As of 2024-12-14, the Intrinsic Value of Xlife Sciences AG (XLS.SW) is
92.49 CHF. This XLS.SW valuation is based on the model Peter Lynch Fair Value.
With the current market price of 26.00 CHF, the upside of Xlife Sciences AG is
255.74%.
92.49 CHF
Intrinsic Value
XLS.SW Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(436.20) - (51.92) |
(85.08) |
-427.2% |
| DCF (Growth 10y) |
(77.76) - (680.16) |
(129.96) |
-599.8% |
| DCF (EBITDA 5y) |
(33.32) - (41.85) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(54.53) - (73.78) |
(1,234.50) |
-123450.0% |
| Fair Value |
92.49 - 92.49 |
92.49 |
255.74% |
| P/E |
58.37 - 158.72 |
103.58 |
298.4% |
| EV/EBITDA |
(17.76) - (17.95) |
(18.07) |
-169.5% |
| EPV |
(6.84) - (5.69) |
(6.27) |
-124.1% |
| DDM - Stable |
42.78 - 335.01 |
188.90 |
626.5% |
| DDM - Multi |
33.61 - 209.11 |
58.36 |
124.5% |
XLS.SW Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
149.24 |
| Beta |
0.87 |
| Outstanding shares (mil) |
5.74 |
| Enterprise Value (mil) |
204.59 |
| Market risk premium |
5.10% |
| Cost of Equity |
7.52% |
| Cost of Debt |
5.50% |
| WACC |
6.56% |